http://orcid.org/0000-0002-7417-7939
References
- Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, et al.: Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP. J Pancreas 13, 497–501, 2012.
- Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, et al.: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369, 1691–1703, 2013.
- Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, et al.: nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 107, dju413, 2015.
- Pinkel D: The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 18, 853–856, 1958.
- Ng M, Fleming T, Robinson M, Thomson B, Graetz N, et al.: Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384, 766–781, 2014.
- Patel AV, Rodriguez C, Bernstein L, Chao A, Thun MJ, et al.: Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. Cohort. Cancer Epidemiol Biomark Prev 14, 459–466, 2005.
- Rollins KE, Tewari N, Ackner A, Awwad A, Madhusudan S, et al.: The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. Clin Nutr 35, 1103–1109, 2015.
- Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, et al.: Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Rese 13, 3264–3268, 2007.
- Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, et al.: A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33, 997–1006, 2008.
- Prado CMM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, et al.: Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9, 629–635, 2008.
- Antoun S, Borget I, and Lanoy E: Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer. Curr Opin Support Palliat Care 7, 383–389, 2013.
- Tewari KS, Java JJ, Gatcliffe TA, Bookman MA, and Monk BJ: Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: An exploratory study of the Gynecologic Oncology Group. Gynecol Oncol 133, 439–445, 2014.
- Kasi PM, Kotani D, Cecchini M, Shitara K, Ohtsu A, et al.: Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. BMC Cancer 16, 467, 2016.